ADGRD2: A G-Protein-Coupled Receptor for Drug Targeting and Biomarker Development

Target Name: ADGRD2

NCBI ID: G347088

ADGRD2

ADGRD2: A G-Protein-Coupled Receptor for Drug Targeting and Biomarker Development

Introduction

G-protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. The seventh member of this family, GPR144 , is a GPCR that has been extensively studied for its potential as a drug target and biomarker. In this article, we will provide an overview of ADGRD2, its structure, function, and potential as a drug target and biomarker.

Structure and Function

ADGRD2 is a 21-kDa GPCR that was identified as a potential drug target in the context of Alzheimer's disease. It is a member of the GPCR family 14, which includes GPR82, GPR83, GPR85, GPR86, GPR87, GPR88, GPR89, GPR91, GPR92, GPR93, GPR94, GPR95, GPR96, GPR97, and GPR98. ADGRD2 is characterized by an extracellular domain containing a single transmembrane region and an intracellular domain that contains a unique GPCR-specific conserved domain.

The N-terminus of ADGRD2 contains a 尾-sheet and a 纬-helix, which are typical of GPCRs. The 尾-sheet is involved in the formation of the N-terminal region, which is known as the N-terminal domain. This region is important for the interactions with G protein-coupled receptors, which are involved in intracellular signaling. The 纬-helix is 鈥嬧?媗ocated at the C-terminus of the N-terminus and is responsible for the formation of the C-terminal region. C-terminus is known as the C-domain and is involved in the interactions with other proteins, including co-factors and ligands.

The unique feature of ADGRD2 is its GPCR-specific conserved domain, which is located between the N-terminus and the 纬-helix. This region is composed of a unique sequence that is conserved across GPCRs, known as the P-type Calcium- Dependent Proline-rich region (PCDR). The PCDR is involved in the regulation of the intracellular signaling pathway, which is critical for the function of the GPCR.

ADGRD2 is a GPCR that is expressed in various tissues, including brain, heart, and pancreas. It is known to be involved in the regulation of neural circuits, including the modulation of neuronal excitability and the control of synaptic plasticity. The role of ADGRD2 in Neural circuits are crucial for the development and progression of various neurological disorders, including Alzheimer's disease.

Drug Targeting and Biomarker Development

ADGRD2 has been identified as a potential drug target due to its unique structure and the involvement of the intracellular signaling pathway. Several studies have demonstrated that blocking the function of ADGRD2 can lead to therapeutic effects in animal models of Alzheimer's disease.

One of the most promising strategies for targeting ADGRD2 is the use of small molecules that can inhibit the activity of the GPCR. Several inhibitors have been identified that can specifically interact with ADGRD2 and block its function. These inhibitors have been shown to improve cognitive function and reduce the formation of neurofibrillary tangles in animal models of Alzheimer's disease.

Another approach to targeting ADGRD2 is the use of antibodies that can specifically recognize and label the protein. These antibodies have been used to study the distribution and function of ADGRD2 in various tissues and have provided insight into the role of ADGRD2 in neural circuits.

Biomarker Development

The development of biomarkers for the early detection and diagnosis of Alzheimer's disease is a major focus of research. ADGRD2 is a potential biomarker for

Protein Name: Adhesion G Protein-coupled Receptor D2

Functions: Orphan receptor

The "ADGRD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets